Five-year experience with Norplant implants in Assiut, Egypt.
This report describes the five-year experience of the first 250 acceptors of NORPLANT implants in Assiut, Egypt. The five-year net continuation rate was 58.6 per 100 women. The five-year net cumulative pregnancy rate was 1.6 per 100 women. About three-fourths of those who continued use of this contraceptive through the fifth year reported having regular cycles. There was definite improvement in the bleeding pattern with time. The five-year net termination rate because of bleeding problems was 17.7 per 100 women. After 5 years of NORPLANT use there was a slight, statistically insignificant increase in weight, systolic and diastolic blood pressures. Of those who used contraceptives after the end of the five-year term of NORPLANT, about one-third opted to have reinsertion of the implants for a second term. About 96% of those who used NORPLANT through the fifth year reported that their experience with the contraceptive had been satisfactory.
D000328:Adult; D000367:Age Factors; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004534:Egypt; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D008597:Menstrual Cycle / Q000187:drug effects; D008599:Menstruation Disturbances / Q000139:chemically induced; D009644:Norgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D010349:Patient Compliance; D011247:Pregnancy; D019736:Prostheses and Implants; D012826:Silicone Elastomers; D014592:Uterine Hemorrhage / Q000139:chemically induced
D012826:Silicone Elastomers; D009644:Norgestrel; D016912:Levonorgestrel